Evidence map›Paper›PMID 34399767›Full record

ArticleMalaria journal2021

Investment case for malaria elimination in South Africa: a financing model for resource mobilization to accelerate regional malaria elimination.

Joseph Njau, Sheetal P Silal, Aparna Kollipara, Katie Fox, Ryleen Balawanth, Anthony Yuen, Lisa J White, Mandisi Moya, Yogan Pillay, Devanand Moonasar

Abstract read
In one paragraph

Article in Malaria journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. The Malaria Burden: A South African Perspective.Journal of tropical medicine · 2024
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Global Cross-Border Malaria Control Collaborative Initiatives: A Scoping Review.International journal of environmental research and public health · 2022
    Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Joseph Njau *JoDon Consulting Group, 4501 Forest View Court, Lilburn, GA, 30047, USA.
Sheetal P Silal *Modelling and Simulation Hub, Africa (MASHA), Department of Statistical Sciences, University of Cape Town, Cape Town, South Africa. sheetal.silal@uct.ac.za.ORCID http://orcid.org/0000-0002-3007-5383
Aparna KolliparaHealth Economist and Health Financing Specialist, California Public Health Department, Sacramento, USA.
Katie FoxDepartment of Global Health at the School of Medicine and Packard Foundation, University of California San Francisco, San Francisco, CA, USA.
Ryleen BalawanthClinton Health Access Initiative (CHAI), South Africa Regional Office, Pretoria, South Africa.
Anthony YuenClinton Health Access Initiative (CHAI), South Africa Regional Office, Pretoria, South Africa.
Lisa J WhiteBig Data Institute, Nuffield Department of Medicine, Li Ka Shing Centre for Health Information and Discovery, University of Oxford, Oxford, UK.
Mandisi MoyaModelling and Simulation Hub, Africa (MASHA), Department of Statistical Sciences, University of Cape Town, Cape Town, South Africa.
Yogan PillayCenter for Innovation in Global Health, Georgetown University, Georgetown, USA.
Devanand MoonasarMalaria Vector and Zoonotic Disease Directorate, National Department of Health, Pretoria, South Africa.

Funding

bill and melinda gates foundation OPP1160129
6 · The paper itself

Abstract

backgroundMalaria continues to be a public health problem in South Africa. While the disease is mainly confined to three of the nine provinces, most local transmissions occur because of importation of cases from neighbouring countries. The government of South Africa has reiterated its commitment to eliminate malaria within its borders. To support the achievement of this goal, this study presents a cost-benefit analysis of malaria elimination in South Africa through simulating different scenarios aimed at achieving malaria elimination within a 10-year period.

methodsA dynamic mathematical transmission model was developed to estimate the costs and benefits of malaria elimination in South Africa between 2018 and 2030. The model simulated a range of malaria interventions and estimated their impact on the transmission of Plasmodium falciparum malaria between 2018 and 2030 in the three endemic provinces of Limpopo, Mpumalanga and KwaZulu-Natal. Local financial, economic, and epidemiological data were used to calibrate the transmission model.

resultsBased on the three primary simulated scenarios: Business as Usual, Accelerate and Source Reduction, the total economic burden was estimated as follows: for the Business as Usual scenario, the total economic burden of malaria in South Africa was R 3.69 billion (USD 223.3 million) over an 11-year period (2018-2029). The economic burden of malaria was estimated at R4.88 billion (USD 295.5 million) and R6.34 billion (~ USD 384 million) for the Accelerate and Source Reduction scenarios, respectively. Costs and benefits are presented in midyear 2020 values. Malaria elimination was predicted to occur in all three provinces if the Source Reduction strategy was adopted to help reduce malaria rates in southern Mozambique. This could be achieved by limiting annual local incidence in South Africa to less than 1 indigenous case with a prediction of this goal being achieved by the year 2026.

conclusionsMalaria elimination in South Africa is feasible and economically worthwhile with a guaranteed positive return on investment (ROI). Findings of this study show that through securing funding for the proposed malaria interventions in the endemic areas of South Africa and neighbouring Mozambique, national elimination could be within reach in an 8-year period.

Indexed as

Disease EradicationHumansMalaria, FalciparumModels, EconomicSouth Africa

Identifiers

PMID34399767
PMCPMC8365569

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.